A physician’s trip through the disease looking glass
June 2, 2014 · Comments Off
Let me tell you about the very rich. They are different from you and me,”...
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
AURORA, Colo -The Journal of Clinical Oncology reports the case of a woman diagnosed with...
CU docs work to boost minorities in (and leading) cancer trials
April 17, 2014 · Comments Off
Focus on training minority investigators By Todd Neff Clinical trials of cancer therapies are most...
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
Layers of Support
December 2, 2013 · Comments Off
Palliative care consult service helps families tailor care to meet personal desires. Barb Cassou was...
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
November 20, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
Reality TV meets reality for lung cancer treatment
June 6, 2013 · Comments Off
By Todd Neff It was Memorial Day Weekend 2012, and Ross Camidge, MD, PhD, was...
NTRK1: a new oncogene and target in lung cancer
June 6, 2013
Wings of Hope to benefit pancreatic cancer research at CU Cancer Center
September 16, 2014 · No comments
A Teal Saturday: Gynecologic Cancer Symposium at CU
September 15, 2014 · No comments
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma microRNA ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
On Sept. 6, the strength and vision of the University of Colorado Cancer Center’s Program of Excellence in... fb.me/1Hb146Pd9
“Sandy is interested in leaving a legacy of innovation to ensure that the University of Colorado has the... fb.me/3APlBMaNV
Great news! fb.me/2rRNa1u1A
A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer... fb.me/3ESuyGbqF